Developer docs
API playgroundTry for free, no card

Search company profiles

Dignitana

Full company profile

uuid00063ne

Namestring
Dignitana
Legal namestring
Dignitana AB (publ)
Websiteurl
dignicap.com
Company typeenum
Public
Founded yearint
1990
Descriptiontext

Dignitana AB (publ) is a Swedish medical technology company that develops, manufactures, and markets the DigniCap Scalp Cooling System, an FDA-cleared Class IIa medical device designed to minimize chemotherapy-induced alopecia in cancer patients with solid tumors. The core technology combines a thermoelectric cooling unit with a flexible silicone-based Cooling Wrap and neoprene Thermal Cap; temperature-regulated coolant (branded DeltaCool) circulates through a labyrinth channel pattern in the wrap, with dual fluid sensors and a backup sensor maintaining consistent scalp temperature. DigniCap received FDA De Novo clearance in December 2015 for breast cancer patients, expanded FDA clearance in 2017 for all solid tumor indications, and FDA clearance for the next-generation DigniCap Delta system in June 2019.

Dignitana generates revenue through a hybrid model: capital equipment (DigniCap Delta and legacy C3 systems) sold or leased directly to hospitals and cancer centers, recurring single-patient-use consumables (Cooling Wraps, Thermal Caps, DeltaCards prepaid treatment credits), per-treatment billing through the myDigniCap.com portal, and US insurance reimbursement under CPT Category I codes as a third-party out-of-network provider. Clinical evidence underpinning the system includes a JAMA-published pivotal trial showing 66.3% hair preservation in breast cancer patients and additional peer-reviewed studies across anthracycline regimens and broader solid-tumor populations. The company is publicly traded on Nasdaq First North Growth Market, with headquarters in Lund, Sweden, a US operations center in Dallas, Texas, and an Italian subsidiary in Milan; distribution extends across roughly 20+ countries through direct enterprise sales and a global network of exclusive and non-exclusive distributors.

Short descriptiontext

Dignitana AB is a Swedish medical technology company that markets the FDA-cleared DigniCap Scalp Cooling System to hospitals and cancer centers, reducing chemotherapy-induced hair loss in solid tumor patients via a thermoelectric cap with single-patient-use consumables.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDallas, United States
HQ citystring
Dallas
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
scalp cooling device, medical device manufacturing, chemotherapy alopecia treatment, oncology supportive care, thermoelectric cooling system
Industry2 codes
1Wound Care & Ulcer Management
CodeHLAKACANPrimaryYes
2Treatments & Scalp Care (Serums, Oils, Anti-dandruff, Growth)
CodeCRABABAEPrimaryNo
NAICS code1 code
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Devices — Oncology Supportive Care
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Device Sales and Leasing
TypeHardware Sales
Description

Dignitana sells or leases DigniCap Delta cooling units to hospitals and cancer treatment centers. The company deploys its equipment at contracted healthcare facilities where scalp cooling services are provided to patients.

news.cision.com
2Single-Patient-Use Consumables
TypeTransaction Fee
Description

Patients purchase single-patient-use consumable components — Cooling Wraps and Thermal Caps — for their treatment series. The DigniCap Delta Kit (single-patient-use components) cannot be returned once received. Treatment Cards (DeltaCards) are prepaid credits for treatment sessions and can be returned for a refund within 6 months of purchase, subject to a $60 restocking fee.

dignicap.com
3Per-Treatment Billing
TypeTransaction Fee
Description

Patients pay per treatment session either through the myDigniCap.com online portal or at the treatment facility. Payment and consent must be provided prior to each treatment session.

dignicap.com
4Insurance Reimbursement
TypeTransaction Fee
Description

Scalp cooling services are billed under CPT Category I codes through Dignitana's insurance-based billing model throughout the United States. As a third-party out-of-network provider, Dignitana does not have direct agreements with insurance companies — reimbursement depends on individual plan coverage. Success with reimbursement varies by plan, coverage, and location.

dignicap.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain
Pricing details4 tiers
1Insurance-covered treatment — CPT Category I billing
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

Scalp cooling is covered by insurance under CPT Category I codes when administered by trained clinical staff in an office or facility setting. As an out-of-network provider, reimbursement varies by insurer, plan, and individual policy. Patients may be responsible for co-pays and minimums.

dignicap.com
2Out-of-pocket per treatment session
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

Patients who are uninsured or whose insurance does not cover scalp cooling pay per session. Payment can be made online through myDigniCap.com or by contacting the Patient Support Center. Payment and consent must be received at least two business days prior to scheduled treatment.

dignicap.com
3DeltaKit — single-patient-use consumables
ModelUnit PricingBilling cadenceOne time/ perpetual license
Notes

The DigniCap Delta Kit is a single-patient-use component and cannot be returned once received — even if unopened or unused.

dignicap.com
4Treatment Cards (DeltaCards)
ModelTransaction based/ take rateBilling cadenceMulti-year contract
Notes

Prepaid treatment credits valid for up to 6 months from purchase date. Unused Treatment Cards may be returned for a refund within 6 months of purchase, subject to a $60 restocking fee per shipment.

dignicap.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1DigniCap Delta
Description

The next generation DigniCap Scalp Cooling System with thermoelectric cooling, form-fitting cap system, and device portability with battery for optimal throughput.

dignicap.com
+1 more record
Core offering1 text field

Dignitana designs, manufactures, and distributes the DigniCap Scalp Cooling System, an FDA-cleared Class IIa medical device that uses thermoelectric cooling and a flexible silicone Cooling Wrap with circulating DeltaCool coolant to reduce chemotherapy-induced hair loss in cancer patients with solid tumors. The company sells or leases the DigniCap Delta device to hospitals and cancer centers and supplies single-patient-use consumables (Cooling Wrap, Thermal Cap, DeltaKit, DeltaCard treatment credits) on a recurring per-treatment basis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 66.3% of breast cancer patients prevented from significant hair loss in pivotal trial vs. 100% hair loss in control group
+4 more records
Product overview1 text field

Dignitana develops and markets The DigniCap Scalp Cooling System, a patented medical device that minimizes chemotherapy-induced hair loss. The product line includes two device models: DigniCap C3 (earlier generation) and DigniCap Delta (next generation with improved flexible wrap and thermal cap system). Both consist of a cooling unit connected to a form-fitting cap that circulates temperature-regulated coolant. The system is FDA cleared for patients with solid tumors and CE certified as Class IIa. Single-patient use components include the Cooling Wrap, Thermal Cap (Delta), and DeltaCool coolant. Consumable Treatment Cards (DeltaCards) enable pre-paid treatment sessions.

Product and service5 records
1DigniCap Delta Scalp Cooling System
CategoryMedical Device — Core Product
Description

Current-generation FDA-cleared scalp cooling medical device consisting of a thermoelectric cooling unit with integrated touchscreen computerized control, connected to a flexible Cooling Wrap and Thermal Cap. Uses circulating DeltaCool temperature-regulated coolant to minimize chemotherapy-induced hair loss in cancer patients with solid tumors. Includes battery capability for device portability and quick-connect hose mechanism.

2DigniCap C3 Scalp Cooling System
CategoryMedical Device — Legacy Product
Description

Earlier generation DigniCap model offering scalp cooling for chemotherapy patients with technical specifications available for clinical reference.

3DeltaKit (Single-Patient-Use Components)
CategoryMedical Device Consumables
Description

Single-patient-use consumable kit including Cooling Wrap and Thermal Cap for the DigniCap Delta system. Non-returnable per FDA medical device regulations.

4DeltaCool Coolant
CategoryMedical Device Consumable
Description

Temperature-regulated coolant that circulates through the DigniCap Delta cooling system from the device via hose to the Cooling Wrap, providing precise scalp temperature control.

5DeltaCard (Treatment Cards)
CategoryTreatment Credit / Prepaid Service
Description

Prepaid treatment cards redeemable for DigniCap Delta sessions, valid for up to 6 months from purchase. Unused cards may be returned for refund within 6 months subject to a $60 per-shipment restocking fee.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2016-12-13
Description

Dignitana partnered with Boa Technology to develop the world's first precision-fit scalp cooling cap. Boa Technology is known for its dial-based closure systems originally developed for snowboard boots, which were adapted to provide a precision fit for the DigniCap cooling cap.

Strategic tierCoreTypeGTM or Marketing Partner
Description

Dignitana is a proud supporter of Susan G. Komen and their mission to save lives by meeting the most critical needs in communities and investing in breakthrough research to prevent and cure breast cancer.

Strategic tierCoreTypeGTM or Marketing Partner
Description

HairToStay is the first and only national nonprofit organization dedicated to helping cancer patients afford scalp cooling. Dignitana partners with HairToStay to provide financial assistance to qualifying patients.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Cold Capital Fund provides financial assistance to chemotherapy patients in Washington DC, Maryland, and Virginia who are trying to prevent hair loss through scalp cooling.

5Hope for Hair Foundation
Strategic tierMinorTypeGTM or Marketing Partner
Description

Hope for Hair Foundation provides support to cancer patients in North Carolina through financial aid for DigniCap treatment and by educating patients about products that help ensure successful hair retention.

dignicap.com
6Cap and Conquer
Strategic tierMinorTypeGTM or Marketing Partner
Description

Cap and Conquer is a 501(c)(3) nonprofit that raises funds for cancer patients in Southeast Michigan who choose to use scalp cooling technology to reduce hair loss during chemotherapy.

dignicap.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Aurora BioScience is the exclusive distributor of DigniCap Delta in Australia and New Zealand, providing local sales, support, and distribution for the DigniCap scalp cooling system in the ANZ region.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Konica Minolta distributes DigniCap in Japan, providing local market access and distribution for the scalp cooling system in the Japanese market.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

OncoMedical AG is the distributor of DigniCap in Switzerland and Liechtenstein, handling local sales and distribution of the scalp cooling system.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Science International Corporation distributes DigniCap in Hong Kong and Macau, providing local market access for the scalp cooling system.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Tesla Medical Solutions distributes DigniCap across the Middle East and North Africa, covering Armenia, Bahrain, Egypt, Iraq, Jordan, Kuwait, Lebanon, Morocco, Oman, Palestine, Qatar, Saudi Arabia, Sudan, Syria, Tunisia, UAE, and Yemen.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Celeritas Trading is the distributor of DigniCap in Mexico, providing local sales and distribution through its DigniCap Mexico directory.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Boosst distributes DigniCap in Ecuador and Peru, providing local market access for the scalp cooling system.

14Chronos Trade Medical
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Chronos Trade Medical distributes DigniCap in Romania.

dignicap.com
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Dignilife distributes DigniCap in Chile, providing local sales and distribution for the scalp cooling system.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Medline is a major medical supplies manufacturer and distributor that supplies hospitals and oncology centers with a broad portfolio including supportive care products. While not a direct scalp cooling competitor, it could leverage its scale and hospital relationships to enter or distribute competing solutions in the supportive oncology care space.

TypeDirect peer
Description

Penguin Cold Caps offers a non-electric, gel-based manual scalp cooling system used by chemotherapy patients. While operating via a different delivery mechanism than DigniCap's thermoelectric approach, it directly competes for the same patient population seeking to prevent chemotherapy-induced hair loss.

TypeBroad incumbent
Description

Smith & Nephew is a major medical device company with established oncology and wound care franchises. While not directly competing in scalp cooling, its scale in medical devices and hospital sales channels makes it a potential acquirer or adjacent entrant into the oncology supportive care device category.

TypeBroad incumbent
Description

Amgen operates in the oncology supportive care space through products like Neulasta (for chemotherapy-induced neutropenia). It represents a broader incumbent addressing adjacent chemotherapy side effects and could expand into alopecia prevention through internal development or acquisition.

5Elasto-Gel (North American Healthcare)
TypeEmerging player
Description

Elasto-Gel manufactures gel-based therapeutic products including cold therapy wraps used in medical settings. It serves adjacent cold therapy applications and could expand into chemotherapy scalp cooling given its existing manufacturing capability in gel-based cooling products.

6Capelli Medical
TypeEmerging player
Description

Capelli Medical develops scalp cooling devices targeting the same oncology supportive care market as DigniCap. As a more recent entrant, it represents an emerging competitive threat with similar product positioning around chemotherapy-induced hair loss prevention.

7Arctic Cold Caps
TypeDirect peer
Description

Arctic Cold Caps provides manual gel-based cold cap systems for chemotherapy patients, primarily operating in the US market. It competes with DigniCap on the same hair-preservation use case but through a lower-cost, patient-managed approach without the controlled cooling technology of DigniCap Delta.

TypeEmerging player
Description

Hilotherm manufactures controlled cooling therapy devices used for post-surgical and chemotherapy-related applications. While focused on broader therapeutic cooling rather than scalp cooling specifically, it operates in the same medical device cooling category and represents an adjacent competitive threat.

TypeDirect peer
Description

Paxman Scalp Cooling is the most direct competitor to Dignitana, also manufacturing and selling thermoelectric scalp cooling systems to oncology centers globally. Both companies target the same clinical use case — preventing chemotherapy-induced alopecia — with similar per-treatment consumables revenue models and competing published clinical evidence.

TypeOthers
Description

Boa Technology is a precision-fit closure technology provider that partnered with Dignitana in 2016 to develop the precision-fit scalp cooling cap. As a technology supplier with existing adjacency to medical device applications, it represents an enabling partner rather than competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Dignitana

Medical Devices — Oncology Supportive Caredignicap.com

Dignitana AB is a Swedish medical technology company that markets the FDA-cleared DigniCap Scalp Cooling System to hospitals and cancer centers, reducing chemotherapy-induced hair loss in solid tumor patients via a thermoelectric cap with single-patient-use consumables.

What Dignitana does

Dignitana AB (publ) is a Swedish medical technology company that develops, manufactures, and markets the DigniCap Scalp Cooling System, an FDA-cleared Class IIa medical device designed to minimize chemotherapy-induced alopecia in cancer patients with solid tumors. The core technology combines a thermoelectric cooling unit with a flexible silicone-based Cooling Wrap and neoprene Thermal Cap; temperature-regulated coolant (branded DeltaCool) circulates through a labyrinth channel pattern in the wrap, with dual fluid sensors and a backup sensor maintaining consistent scalp temperature. DigniCap received FDA De Novo clearance in December 2015 for breast cancer patients, expanded FDA clearance in 2017 for all solid tumor indications, and FDA clearance for the next-generation DigniCap Delta system in June 2019.

Dignitana generates revenue through a hybrid model: capital equipment (DigniCap Delta and legacy C3 systems) sold or leased directly to hospitals and cancer centers, recurring single-patient-use consumables (Cooling Wraps, Thermal Caps, DeltaCards prepaid treatment credits), per-treatment billing through the myDigniCap.com portal, and US insurance reimbursement under CPT Category I codes as a third-party out-of-network provider. Clinical evidence underpinning the system includes a JAMA-published pivotal trial showing 66.3% hair preservation in breast cancer patients and additional peer-reviewed studies across anthracycline regimens and broader solid-tumor populations. The company is publicly traded on Nasdaq First North Growth Market, with headquarters in Lund, Sweden, a US operations center in Dallas, Texas, and an Italian subsidiary in Milan; distribution extends across roughly 20+ countries through direct enterprise sales and a global network of exclusive and non-exclusive distributors.

Dignitana firmographics

Firmographics
Name
Dignitana
Legal name
Dignitana AB (publ)
Website
https://dignicap.com
Company type
Public
Founded year
1990
Operating status
Operating
Headcount range
11–50 employees
Short description
Dignitana AB is a Swedish medical technology company that markets the FDA-cleared DigniCap Scalp Cooling System to hospitals and cancer centers, reducing chemotherapy-induced hair loss in solid tumor patients via a thermoelectric cap with single-patient-use consumables.
Ownership category
akta.pro rank

Dignitana industry classification

Industry
Product category
Medical Devices — Oncology Supportive Care
NAICS
Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Wound Care & Ulcer Management (HLAKACAN)
akta.pro secondary industry
Treatments & Scalp Care (Serums, Oils, Anti-dandruff, Growth) (CRABABAE)

Keywords

  • Scalp cooling device
  • Medical device manufacturing
  • Chemotherapy alopecia treatment
  • Oncology supportive care
  • Thermoelectric cooling system

Where Dignitana is headquartered

Location

Headquarters

HQ city
Dallas
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Dignitana business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Revenue model

  1. Device Sales and Leasing: Dignitana sells or leases DigniCap Delta cooling units to hospitals and cancer treatment centers. The company deploys its equipment at contracted healthcare facilities where scalp cooling services are provided to patients.
  2. Single-Patient-Use Consumables: Patients purchase single-patient-use consumable components — Cooling Wraps and Thermal Caps — for their treatment series. The DigniCap Delta Kit (single-patient-use components) cannot be returned once received. Treatment Cards (DeltaCards) are prepaid credits for treatment sessions and can be returned for a refund within 6 months of purchase, subject to a $60 restocking fee.
  3. Per-Treatment Billing: Patients pay per treatment session either through the myDigniCap.com online portal or at the treatment facility. Payment and consent must be provided prior to each treatment session.
  4. Insurance Reimbursement: Scalp cooling services are billed under CPT Category I codes through Dignitana's insurance-based billing model throughout the United States. As a third-party out-of-network provider, Dignitana does not have direct agreements with insurance companies — reimbursement depends on individual plan coverage. Success with reimbursement varies by plan, coverage, and location.

Pricing tiers

ModelBillingPrice
Transaction based/ take ratePay-as-you-goInsurance-covered treatment — CPT Category I billing
Transaction based/ take ratePay-as-you-goOut-of-pocket per treatment session
Unit PricingOne time/ perpetual licenseDeltaKit — single-patient-use consumables
Transaction based/ take rateMulti-year contractTreatment Cards (DeltaCards)

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Dignitana product offering

Product offering

Core offering

Dignitana designs, manufactures, and distributes the DigniCap Scalp Cooling System, an FDA-cleared Class IIa medical device that uses thermoelectric cooling and a flexible silicone Cooling Wrap with circulating DeltaCool coolant to reduce chemotherapy-induced hair loss in cancer patients with solid tumors. The company sells or leases the DigniCap Delta device to hospitals and cancer centers and supplies single-patient-use consumables (Cooling Wrap, Thermal Cap, DeltaKit, DeltaCard treatment credits) on a recurring per-treatment basis.

Product overview

Dignitana develops and markets The DigniCap Scalp Cooling System, a patented medical device that minimizes chemotherapy-induced hair loss. The product line includes two device models: DigniCap C3 (earlier generation) and DigniCap Delta (next generation with improved flexible wrap and thermal cap system). Both consist of a cooling unit connected to a form-fitting cap that circulates temperature-regulated coolant. The system is FDA cleared for patients with solid tumors and CE certified as Class IIa. Single-patient use components include the Cooling Wrap, Thermal Cap (Delta), and DeltaCool coolant. Consumable Treatment Cards (DeltaCards) enable pre-paid treatment sessions.

Differentiator

Problem solved

Functional benefit

Brands

  • DigniCap Delta: The next generation DigniCap Scalp Cooling System with thermoelectric cooling, form-fitting cap system, and device portability with battery for optimal throughput.
  • DeltaCool

Products and services

  • DigniCap Delta Scalp Cooling System Current-generation FDA-cleared scalp cooling medical device consisting of a thermoelectric cooling unit with integrated touchscreen computerized control, connected to a flexible Cooling Wrap and Thermal Cap. Uses circulating DeltaCool temperature-regulated coolant to minimize chemotherapy-induced hair loss in cancer patients with solid tumors. Includes battery capability for device portability and quick-connect hose mechanism.
  • DigniCap C3 Scalp Cooling System Earlier generation DigniCap model offering scalp cooling for chemotherapy patients with technical specifications available for clinical reference.
  • DeltaKit (Single-Patient-Use Components) Single-patient-use consumable kit including Cooling Wrap and Thermal Cap for the DigniCap Delta system. Non-returnable per FDA medical device regulations.
  • DeltaCool Coolant Temperature-regulated coolant that circulates through the DigniCap Delta cooling system from the device via hose to the Cooling Wrap, providing precise scalp temperature control.
  • DeltaCard (Treatment Cards) Prepaid treatment cards redeemable for DigniCap Delta sessions, valid for up to 6 months from purchase. Unused cards may be returned for refund within 6 months subject to a $60 per-shipment restocking fee.

Quantifiable outcome

  • 66.3% of breast cancer patients prevented from significant hair loss in pivotal trial vs. 100% hair loss in control group
  • +4 more outcomes

Companies that use Dignitana

Customer profile

Named customers10 records

Segments3 records

Ideal customer profiles3 records

Dignitana technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

Feature6 records

Dignitana partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered core and minor.

  • Boa TechnologycoreTechnology or Integration · 13 December 2016Dignitana partnered with Boa Technology to develop the world's first precision-fit scalp cooling cap. Boa Technology is known for its dial-based closure systems originally developed for snowboard boots, which were adapted to provide a precision fit for the DigniCap cooling cap.
  • Susan G. KomencoreGTM or Marketing PartnerDignitana is a proud supporter of Susan G. Komen and their mission to save lives by meeting the most critical needs in communities and investing in breakthrough research to prevent and cure breast cancer.
  • HairToStaycoreGTM or Marketing PartnerHairToStay is the first and only national nonprofit organization dedicated to helping cancer patients afford scalp cooling. Dignitana partners with HairToStay to provide financial assistance to qualifying patients.
  • Cold Capital FundminorGTM or Marketing PartnerCold Capital Fund provides financial assistance to chemotherapy patients in Washington DC, Maryland, and Virginia who are trying to prevent hair loss through scalp cooling.
  • Hope for Hair FoundationminorGTM or Marketing PartnerHope for Hair Foundation provides support to cancer patients in North Carolina through financial aid for DigniCap treatment and by educating patients about products that help ensure successful hair retention.
  • Cap and ConquerminorGTM or Marketing PartnerCap and Conquer is a 501(c)(3) nonprofit that raises funds for cancer patients in Southeast Michigan who choose to use scalp cooling technology to reduce hair loss during chemotherapy.
  • Aurora BioScience Pty LtdcoreChannel Partner/ Reseller/ DistributorAurora BioScience is the exclusive distributor of DigniCap Delta in Australia and New Zealand, providing local sales, support, and distribution for the DigniCap scalp cooling system in the ANZ region.
  • Konica MinoltacoreChannel Partner/ Reseller/ DistributorKonica Minolta distributes DigniCap in Japan, providing local market access and distribution for the scalp cooling system in the Japanese market.
  • OncoMedical AGcoreChannel Partner/ Reseller/ DistributorOncoMedical AG is the distributor of DigniCap in Switzerland and Liechtenstein, handling local sales and distribution of the scalp cooling system.
  • Science International CorporationcoreChannel Partner/ Reseller/ DistributorScience International Corporation distributes DigniCap in Hong Kong and Macau, providing local market access for the scalp cooling system.
  • Tesla Medical SolutionscoreChannel Partner/ Reseller/ DistributorTesla Medical Solutions distributes DigniCap across the Middle East and North Africa, covering Armenia, Bahrain, Egypt, Iraq, Jordan, Kuwait, Lebanon, Morocco, Oman, Palestine, Qatar, Saudi Arabia, Sudan, Syria, Tunisia, UAE, and Yemen.
  • Celeritas TradingcoreChannel Partner/ Reseller/ DistributorCeleritas Trading is the distributor of DigniCap in Mexico, providing local sales and distribution through its DigniCap Mexico directory.
  • BoosstminorChannel Partner/ Reseller/ DistributorBoosst distributes DigniCap in Ecuador and Peru, providing local market access for the scalp cooling system.
  • Chronos Trade MedicalminorChannel Partner/ Reseller/ DistributorChronos Trade Medical distributes DigniCap in Romania.
  • DignilifeminorChannel Partner/ Reseller/ DistributorDignilife distributes DigniCap in Chile, providing local sales and distribution for the scalp cooling system.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Dignitana competitors and assessment

Company assessment

Broad incumbents

  • Medline Industries: Medline is a major medical supplies manufacturer and distributor that supplies hospitals and oncology centers with a broad portfolio including supportive care products. While not a direct scalp cooling competitor, it could leverage its scale and hospital relationships to enter or distribute competing solutions in the supportive oncology care space.
  • Smith & Nephew: Smith & Nephew is a major medical device company with established oncology and wound care franchises. While not directly competing in scalp cooling, its scale in medical devices and hospital sales channels makes it a potential acquirer or adjacent entrant into the oncology supportive care device category.
  • Amgen (Neulasta / supportive care portfolio): Amgen operates in the oncology supportive care space through products like Neulasta (for chemotherapy-induced neutropenia). It represents a broader incumbent addressing adjacent chemotherapy side effects and could expand into alopecia prevention through internal development or acquisition.

Direct peers

  • Penguin Cold Caps: Penguin Cold Caps offers a non-electric, gel-based manual scalp cooling system used by chemotherapy patients. While operating via a different delivery mechanism than DigniCap's thermoelectric approach, it directly competes for the same patient population seeking to prevent chemotherapy-induced hair loss.
  • Arctic Cold Caps: Arctic Cold Caps provides manual gel-based cold cap systems for chemotherapy patients, primarily operating in the US market. It competes with DigniCap on the same hair-preservation use case but through a lower-cost, patient-managed approach without the controlled cooling technology of DigniCap Delta.
  • Paxman Scalp Cooling: Paxman Scalp Cooling is the most direct competitor to Dignitana, also manufacturing and selling thermoelectric scalp cooling systems to oncology centers globally. Both companies target the same clinical use case — preventing chemotherapy-induced alopecia — with similar per-treatment consumables revenue models and competing published clinical evidence.

Emerging players

  • Elasto-Gel (North American Healthcare): Elasto-Gel manufactures gel-based therapeutic products including cold therapy wraps used in medical settings. It serves adjacent cold therapy applications and could expand into chemotherapy scalp cooling given its existing manufacturing capability in gel-based cooling products.
  • Capelli Medical: Capelli Medical develops scalp cooling devices targeting the same oncology supportive care market as DigniCap. As a more recent entrant, it represents an emerging competitive threat with similar product positioning around chemotherapy-induced hair loss prevention.
  • Hilotherm: Hilotherm manufactures controlled cooling therapy devices used for post-surgical and chemotherapy-related applications. While focused on broader therapeutic cooling rather than scalp cooling specifically, it operates in the same medical device cooling category and represents an adjacent competitive threat.

Others

  • Boa Technology: Boa Technology is a precision-fit closure technology provider that partnered with Dignitana in 2016 to develop the precision-fit scalp cooling cap. As a technology supplier with existing adjacency to medical device applications, it represents an enabling partner rather than competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Dignitana social profiles

Digital presence

Dignitana compliance and trust

Trust signal

Compliance6 records

Dignitana financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Dignitana leadership team

Management profile

Number of profiles

Profiles1 record

Dignitana subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Dignitana funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Dignitana M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dignitana

What does Dignitana do?

Dignitana designs, manufactures, and distributes the DigniCap Scalp Cooling System, an FDA-cleared Class IIa medical device that uses thermoelectric cooling and a flexible silicone Cooling Wrap with circulating DeltaCool coolant to reduce chemotherapy-induced hair loss in cancer patients with solid tumors. The company sells or leases the DigniCap Delta device to hospitals and cancer centers and supplies single-patient-use consumables (Cooling Wrap, Thermal Cap, DeltaKit, DeltaCard treatment credits) on a recurring per-treatment basis.

Is Dignitana a public or private company?

Dignitana is a public company. It is classified as public and is currently operating.

When was Dignitana founded?

Dignitana was founded in 1990. It employs 11 to 50 people.

Where is Dignitana based?

Dignitana is headquartered in Dallas, United States, in the North America region.

How does Dignitana make money?

Four revenue lines are on record. Device Sales and Leasing is the primary driver. The others are single-Patient-Use Consumables, per-Treatment Billing and insurance Reimbursement.

Who are Dignitana's main competitors?

Broad incumbents on record are Medline Industries, Smith & Nephew and Amgen (Neulasta / supportive care portfolio). Direct peers are Penguin Cold Caps, Arctic Cold Caps and Paxman Scalp Cooling. Emerging players are Elasto-Gel (North American Healthcare), Capelli Medical and Hilotherm. Boa Technology is listed as an others.

Does Dignitana have an API?

No public API is recorded for Dignitana.

What industry is Dignitana in?

Dignitana's product category is Medical Devices — Oncology Supportive Care. Its primary akta.pro industry code is HLAKACAN, Wound Care & Ulcer Management, with a secondary code of CRABABAE, Treatments & Scalp Care (Serums, Oils, Anti-dandruff, Growth). Its NAICS code is 3391 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireDigniCap long-term study demonstrates safety and efficacy of scalp cooling to reduce chemo hair lossDignitana AB reported that a five-year long-term study of its DigniCap Scalp Cooling System, published in Supportive Care in Cancer, confirms the therapy's safety and efficacy in preventing chemotherapy-induced hair loss without increasing metastasis risk. The study highlights that 66.3% of patients retained the majority of their hair in the pivotal trial, with next-generation devices showing even higher satisfaction rates. This publication validates the clinical data that led to the device's initial FDA clearance in the United States.news.cision.comDignitana announces directed share issue of approximately SEK 25 millionDignitana AB's Board resolved on a directed share issue of 5,415,000 new shares at SEK 4.59 each to Agartha AB, Handelsbanken Fonder and Swedbank Robur, raising about SEK 25 million before transaction costs. The issue dilutes existing shareholders by roughly 7.7 percent and will fund growth initiatives and working capital.PR NewswireDignitana Announces Decision by Medicare to Reassign Payment for Scalp CoolingDignitana, a Swedish medical device company, announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has reassigned payment for scalp cooling treatment (CPT code 0662T) to New Technology APC 1520 with a national average payment of $1,850.50, effective January 1, 2022. This represents a significant increase from the previously proposed rate of $34.72, making the therapy financially accessible for Medicare beneficiaries. The decision enables facility reimbursement under Medicare's Hospital Outpatient Prospective Payment System, expanding access to DigniCap Scalp Cooling for cancer patients undergoing chemotherapy.PR NewswireDignitana launches new initiatives to support reimbursement and market accessDignitana announced the launch of two initiatives — a reimbursement hub and an appeal support program — to assist U.S. providers of The DigniCap Scalp Cooling System, partnering with Minneapolis-based consulting firms JD Lymon Group and JDL Access. The initiatives are timed to coincide with the July 1 introduction of CPT codes for scalp cooling, addressing what the company describes as complexities in the reimbursement landscape. Dignitana CEO William Cronin noted an accelerated pace of new provider sign-ups and expressed confidence that increased reimbursement access will drive further awareness and utilization of DigniCap, advancing the company's strategic objectives.PR NewswireDignitana expands agreement with GenesisCare to include United StatesDignitana AB signed an agreement with GenesisCare to expand their preferred provider network for DigniCap scalp cooling systems to include GenesisCare locations in the United States, building on an initial agreement covering Australia announced in December 2020. The DigniCap system minimizes hair loss from chemotherapy in patients with solid tumors, and GenesisCare selected Dignitana based on improved patient outcomes, ease of use, and COVID-19 protocol compatibility. U.S. implementation will begin with DigniCap Delta installations in Florida this spring.GlobeNewswireTrading in subscription rights (TR) and paid subscription shares (BTA) in Dignitana AB (publ) (449/18)Dignitana AB will trade its subscription rights (TR) and paid subscription shares (BTA) on First North starting December 4, 2018. TR trading ends December 14, 2018, while BTA trading continues until further notice. The instruments carry ISIN codes SE0012011054 and SE0012011062.GlobeNewswireTrading in subscription rights (TR) and paid subscription shares (BTA) in Dignitana AB (361/17)Dignitana AB's subscription rights and paid subscription shares will trade on First North starting December 8, 2017, with rights trading until December 20, 2017. The instruments carry ISIN codes SE0010636514 and SE0010636522, respectively, and are listed under Other Equities.GlobeNewswireDignitana AB receives observation status (306/17)Nasdaq Stockholm gave Dignitana AB observation status on October 27, 2017, because its working capital is sufficient only until mid-November 2017. The decision follows First North rules that allow observation status for material adverse uncertainty in a company's financial situation.PR NewswireFDA clears expanded use of cooling cap to reduce hair loss during chemotherapyThe FDA cleared the expanded use of the DigniCap Cooling System on July 3, 2017, making it the first cooling cap authorized for use in cancer patients with solid tumors beyond breast cancer. The system works by cooling the scalp to constrict blood vessels, reducing chemotherapy exposure to hair follicles, with clinical data showing over 66 percent of patients retaining more than half their hair. The FDA granted clearance to Dignitana Inc. for the expanded indication based on peer-reviewed evidence supporting safety and efficacy.PR NewswireMemorial Sloan Kettering to Offer DigniCap® Scalp Cooling Device in New York Metro Area LocationsDignitana AB announced that its FDA-cleared DigniCap® scalp cooling system will be available at Memorial Sloan Kettering Cancer Center facilities across the New York metro area, including eight outpatient locations in New York, New Jersey, and Long Island. MSK has ordered 17 units of the device, which reduces chemotherapy-induced hair loss in women with breast cancer, making this the largest scalp-cooling installation at any medical center in the US to date. The system will be launched at MSK facilities in Spring 2017 after nearly 100 nurses and medical personnel receive training.